Glio-XS15 Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma (Aktiv)
INTRAGO II A multicenter randomized Phase III Trial in INTraoperative RAdiotherapy in newly diagnosed GliOblastoam multiforme (INTRAGO II) (Aktiv)
NOA-20 In this trial patients with newly diagnosed glioblastoma with an unmethylated MGMT-promoter are treated with targeted substances according to the results of a molecular and genomic characterization of their tumor tissue. One out of 8 drugs is given to the patient in combination with radiotherapy. (Aktiv)
RESURGE Surgery for Recurrent Glioblastoma (RESURGE) (Aktiv)
TRIDENT EF-32 EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (Aktiv)
Zweitlinie oder später
Car2Brain Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001) (CAR2BRAIN) (Aktiv)
EOGBM1-18 First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (Aktiv)
GIRO Phase III Studie zur erneuten Bestrahlung mit Kohlenstoffionen oder Photonen als Zweitlinientherapie bei Glioblastom (Aktiv)
HIT-HGG-Rez-Immunovac Autologous Dendritic Cells and Metronomic Cyclophosphamide for Relapsed High-Grade Gliomas in Children and Adolescents HIT-HGG-Rez-Immunovac - A Clinical Phase I/II Trial of the HIT-HGG Study Group - (Aktiv)
MecMeth Phase I/II Studie zu Meclofenamate als Zweitlinientherapie bei Glioblastom-Rezidiv mit methyliertem MGMT-Promotor (Aktiv)
RESURGE Surgery for Recurrent Glioblastoma (RESURGE) (Aktiv)
VXM01-AVE-04-INT An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery. (Aktiv)